Preemptive Therapy with Anidulafungin

PreclinicalSmall molecule

Preemptive Therapy with Anidulafungin is one of 7 small molecule programs targeting Candidiasis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CandidiasisActive, not recruiting

CandidiasisPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Candidiasis

#DrugCompanyPhaseTrials

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

15 2

Mycamine

BBaxter Healthcare Corporation

Approved

12 3

Cancidas

FFresenius Kabi Taiwan Ltd.

Approved

7 4

Eraxis

VVicuron Pharmaceuticals

Approved

4 5

Sporanox

SSebela Pharmaceuticals Development LLC

Approved

2 6

Vfend

PPrism Pharmaceuticals

Approved

2 7

Preemptive Therapy with Anidulafungin

DDuke University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Candidiasis1 trial

β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients

Completed·—·N/A·NCT00672841·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Preemptive Therapy with Anidulafungin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Preemptive Therapy with Anidulafungin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Preemptive Therapy with Anidulafungin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Duke University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: DDuke University

Preemptive Therapy with Anidulafungin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Candidiasis1 trial

References

Drug Info

Quick Facts

Related News